Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074161793> ?p ?o ?g. }
- W2074161793 abstract "Well-differentiated neuroendocrine carcinomas are highly vascularized and may be sensitive to drugs administered on a metronomic schedule that has shown antiangiogenic properties. A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma.Twenty-nine patients with metastatic or locally advanced well-differentiated neuroendocrine carcinoma were treated with protracted 5FU intravenous infusion (200 mg/m2 daily) plus LAR octreotide (20 mg monthly). Patients were followed for toxicity, objective response, symptomatic and biochemical response, time to progression and survival.Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria showed partial response in 7 (24.1%), stable disease in 20 (69.0%), and disease progression in 2 patients. Response did not significantly differ when patients were stratified by primary tumor site and proliferative activity. A biochemical (chromogranin A) response was observed in 12/25 assessable patients (48.0%); symptom relief was obtained in 9/15 symptomatic patients (60.0%). There was non significant decrease in circulating vascular epithelial growth factor (VEGF) over time. Median time to progression was 22.6 months (range, 2.7-68.5); median overall survival was not reached yet. Toxicity was mild and manageable.Continuous/metronomic 5FU infusion plus LAR octreotide is well tolerated and shows activity in patients with well-differentiated neuroendocrine carcinoma. The potential synergism between metronomic chemotherapy and antiangiogenic drugs provides a rationale for exploring this association in the future.NCT00953394." @default.
- W2074161793 created "2016-06-24" @default.
- W2074161793 creator A5017298616 @default.
- W2074161793 creator A5020736353 @default.
- W2074161793 creator A5022022429 @default.
- W2074161793 creator A5022660275 @default.
- W2074161793 creator A5024088672 @default.
- W2074161793 creator A5026006211 @default.
- W2074161793 creator A5034042399 @default.
- W2074161793 creator A5034806738 @default.
- W2074161793 creator A5050426287 @default.
- W2074161793 creator A5050466636 @default.
- W2074161793 creator A5051062219 @default.
- W2074161793 creator A5053922174 @default.
- W2074161793 creator A5069480724 @default.
- W2074161793 creator A5075637844 @default.
- W2074161793 creator A5077674568 @default.
- W2074161793 date "2009-11-03" @default.
- W2074161793 modified "2023-09-26" @default.
- W2074161793 title "Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network" @default.
- W2074161793 cites W103592546 @default.
- W2074161793 cites W1625637014 @default.
- W2074161793 cites W1968626722 @default.
- W2074161793 cites W1972201939 @default.
- W2074161793 cites W1977347411 @default.
- W2074161793 cites W1990509102 @default.
- W2074161793 cites W1993221176 @default.
- W2074161793 cites W2003278673 @default.
- W2074161793 cites W2029409133 @default.
- W2074161793 cites W2042265119 @default.
- W2074161793 cites W2053262936 @default.
- W2074161793 cites W2063178653 @default.
- W2074161793 cites W2066768964 @default.
- W2074161793 cites W2069387784 @default.
- W2074161793 cites W2100283328 @default.
- W2074161793 cites W2104316189 @default.
- W2074161793 cites W2107276199 @default.
- W2074161793 cites W2124257017 @default.
- W2074161793 cites W2131475382 @default.
- W2074161793 cites W2139248078 @default.
- W2074161793 cites W2149536932 @default.
- W2074161793 cites W2155161822 @default.
- W2074161793 cites W2163940216 @default.
- W2074161793 cites W2164614522 @default.
- W2074161793 cites W2169965478 @default.
- W2074161793 cites W2170518806 @default.
- W2074161793 cites W2172015344 @default.
- W2074161793 cites W2263116899 @default.
- W2074161793 cites W2339290868 @default.
- W2074161793 cites W4236245864 @default.
- W2074161793 doi "https://doi.org/10.1186/1471-2407-9-388" @default.
- W2074161793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2776604" @default.
- W2074161793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19886987" @default.
- W2074161793 hasPublicationYear "2009" @default.
- W2074161793 type Work @default.
- W2074161793 sameAs 2074161793 @default.
- W2074161793 citedByCount "58" @default.
- W2074161793 countsByYear W20741617932012 @default.
- W2074161793 countsByYear W20741617932013 @default.
- W2074161793 countsByYear W20741617932014 @default.
- W2074161793 countsByYear W20741617932015 @default.
- W2074161793 countsByYear W20741617932016 @default.
- W2074161793 countsByYear W20741617932017 @default.
- W2074161793 countsByYear W20741617932018 @default.
- W2074161793 countsByYear W20741617932019 @default.
- W2074161793 countsByYear W20741617932021 @default.
- W2074161793 countsByYear W20741617932022 @default.
- W2074161793 countsByYear W20741617932023 @default.
- W2074161793 crossrefType "journal-article" @default.
- W2074161793 hasAuthorship W2074161793A5017298616 @default.
- W2074161793 hasAuthorship W2074161793A5020736353 @default.
- W2074161793 hasAuthorship W2074161793A5022022429 @default.
- W2074161793 hasAuthorship W2074161793A5022660275 @default.
- W2074161793 hasAuthorship W2074161793A5024088672 @default.
- W2074161793 hasAuthorship W2074161793A5026006211 @default.
- W2074161793 hasAuthorship W2074161793A5034042399 @default.
- W2074161793 hasAuthorship W2074161793A5034806738 @default.
- W2074161793 hasAuthorship W2074161793A5050426287 @default.
- W2074161793 hasAuthorship W2074161793A5050466636 @default.
- W2074161793 hasAuthorship W2074161793A5051062219 @default.
- W2074161793 hasAuthorship W2074161793A5053922174 @default.
- W2074161793 hasAuthorship W2074161793A5069480724 @default.
- W2074161793 hasAuthorship W2074161793A5075637844 @default.
- W2074161793 hasAuthorship W2074161793A5077674568 @default.
- W2074161793 hasBestOaLocation W20741617931 @default.
- W2074161793 hasConcept C121608353 @default.
- W2074161793 hasConcept C126322002 @default.
- W2074161793 hasConcept C143998085 @default.
- W2074161793 hasConcept C204232928 @default.
- W2074161793 hasConcept C2776297358 @default.
- W2074161793 hasConcept C2776694085 @default.
- W2074161793 hasConcept C2777546739 @default.
- W2074161793 hasConcept C2778822529 @default.
- W2074161793 hasConcept C2779066768 @default.
- W2074161793 hasConcept C2779984678 @default.
- W2074161793 hasConcept C2780140570 @default.
- W2074161793 hasConcept C2780192828 @default.
- W2074161793 hasConcept C2780341458 @default.
- W2074161793 hasConcept C2780456651 @default.
- W2074161793 hasConcept C2781025020 @default.